Ashvany Bansal on How Mamosure Is Bringing Preventive Cancer Care Within Reach

StartupTalky presents Recap'25, a series of exclusive interviews where we connect with founders and industry leaders to reflect on their journey in 2025 and discuss their vision for the future.

In this edition of Recap’25, StartupTalky speaks with Ashvany Bansal, Founder & CMD of Mamosure, who reflects on a defining year shaped by scientific validation, global patent recognition, and the transition from years of deep research to real-world accessibility. Bansal shares how Mamosure’s decade-long phyto-therapeutic research journey culminated in an affordable breast cancer prevention solution, the milestones achieved in patents, government support, and product rollout, and the challenges of building awareness as a bootstrapped healthcare innovator. He also discusses the philosophy of true prevention, the role of indigenous R&D in cost-efficient healthcare, and Mamosure’s vision to expand preventive cancer care and positively impact millions of lives globally in 2026.

StartupTalky: For readers who may not be familiar with your work, how would you describe Mamosure and  the kind of healthcare products you are focused on developing and manufacturing? 

Ashvany Bansal: Mamosure is a revolutionary Wellness product for Breast Cancer Prevention. It increases immunity of the body and selectively kills cancerous cells without harming  the healthy cells.  

The product is developed after 10 years of research and scientific studies conducted in the prestigious institutes like ACTREC-TMC, and Haffkine Institute in India. Mamosure is a simple oral product - a person shall add 8 drops in lukewarm water, or  butter milk, or natural juice, or milk and drink in the morning for 90 days to get  protection from Breast Cancer. 

There are about 30 trillion cells in human body, and some will naturally have errors or  damaged DNA. Cancer happens when body cells lose control, start growing  abnormally, and form a lump or spread to other parts of the body. 

The immune system in human body acts like a security guard, identifying and  destroying these cancerous cells before they become problematic and harmful. Chronic exposure to environmental pollution and synthetic chemicals present in  daily consumables can disrupt normal cellular regulation. Mamosure is developed  as a Phyto-therapeutic product to support the body’s internal defence mechanisms  and help maintain cellular health under such environmental stressors. 

StartupTalky: What was the motivation behind starting Mamosure, and how did the vision of making  treatments for critical diseases more affordable take shape? 

Ashvany Bansal: Cancer is a life-threatening disease that affects millions of lives worldwide. It  severally affects the patients & their family emotionally, financially and  psychologically. We are a deep-tech medicine research organisation, working on an  affordable, easily accessible cancer prevention product which is highly efficacious  and does not have side effects as against present available treatments.  

StartupTalky: In 2025, what key developments or milestones did Mamosure achieve across research,  product development, or manufacturing? 

Ashvany Bansal: In 2025, Mamosure has received international patents granted and got  acknowledged by Government of Maharashtra by providing grant amount for the  achievement of the company. The branding of the final product is created, and it is  now available on our website https://mamosure.com and availability in hospitals are  being done. 

StartupTalky: Affordability is central to your mission. What would you highlight as Mamosure’s key USPs in  delivering effective treatments for critical diseases at accessible prices? 

Ashvany Bansal: We focus on true prevention. “True prevention means stopping a disease before it  starts, not just finding it early.” Stopping a disease from developing in the first place,  not just detecting it early. Therefore, Prevention is better than cure. 

The key strengths of the product include: 

• Priced affordably to ensure wider reach and long-term accessibility. ii. Designed for easy availability, including in remote and rural regions of India.
• Simple oral administration, requiring no specialised equipment or technical  expertise. 
• Developed to act selectively on abnormal cells while supporting the protection of  healthy cells, based on its Phyto-therapeutic mechanism. v. Aims to reduce disease-related discomfort and improve quality of life by supporting  the body through gentler, non-invasive care. 

StartupTalky: How does Mamosure approach research and innovation to ensure both quality and cost efficiency in healthcare solutions? 

Ashvany Bansal: Mamosure is an IPR product, patented in India and 11 other countries. The product  is made of finest quality best ingredients. The cost of cancer treatment and relapse  cases goes up to Rs 1-5 crore, while our product’s price is only a few thousand  rupees. It is 100% indigenously researched, developed, and IPR protected product. 

StartupTalky: What was one major challenge you faced in 2025 while operating in the critical healthcare  and manufacturing space, and what did it teach you? 

Ashvany Bansal: Marketing of a high quality and efficacious product by a boot strapped company is a  challenge. We will request readers of this article to spread awareness by informing  about https://mamosure.com to 3 of their friends / family / colleagues, so that they  can get benefitted by it in case of necessity.  

StartupTalky: Based on your journey so far, what one practical piece of advice would you share with  founders building mission-driven healthcare companies? 

Ashvany Bansal: Our advice to founders building mission-driven healthcare companies is that this  space requires a great amount of patience and resources. The challenges are  enormous such as delay in conducting testing, IPR takes about 5-6 years for getting  international patents, inclusion of the product in formulary of established institutions etc.. 

StartupTalky: Looking ahead to 2026, what are Mamosure’s key priorities as you work towards increasing  life expectancy through global market presence? 

Ashvany Bansal: In 2026, The key objectives are as follows: 

• To spread awareness about the health impact of cancer and educate people on  preventive measures and safeguards. 
• To continuously develop scientifically driven products addressing different types of  cancer as part of our long-term mission. Building on our success across multiple cancer related indications, we aim to positively impact the lives of one crore people every year through awareness, prevention, and supportive care.

Explore more Recap'25 interviews here.